$1.92 Billion in Sales Expected for Quest Diagnostics Inc (NYSE:DGX) This Quarter

Brokerages predict that Quest Diagnostics Inc (NYSE:DGX) will post $1.92 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Quest Diagnostics’ earnings. The lowest sales estimate is $1.91 billion and the highest is $1.92 billion. Quest Diagnostics posted sales of $1.84 billion in the same quarter last year, which suggests a positive year over year growth rate of 4.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, February 13th.

On average, analysts expect that Quest Diagnostics will report full-year sales of $7.72 billion for the current year, with estimates ranging from $7.71 billion to $7.72 billion. For the next year, analysts anticipate that the company will report sales of $7.89 billion, with estimates ranging from $7.82 billion to $7.96 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $1.76 EPS for the quarter, topping the Zacks’ consensus estimate of $1.71 by $0.05. Quest Diagnostics had a return on equity of 15.32% and a net margin of 9.58%. The firm had revenue of $1.96 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period last year, the company earned $1.68 earnings per share. The company’s revenue was up 3.5% on a year-over-year basis.

Several analysts have issued reports on DGX shares. Credit Suisse Group raised their price objective on shares of Quest Diagnostics from $99.00 to $105.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Zacks Investment Research raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 price objective on the stock in a report on Monday, September 30th. UBS Group cut their price target on shares of Quest Diagnostics from $103.00 to $102.00 and set a “neutral” rating on the stock in a report on Monday, October 21st. Evercore ISI reaffirmed a “buy” rating and issued a $108.00 price target on shares of Quest Diagnostics in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Quest Diagnostics from $100.00 to $111.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $105.27.

NYSE DGX traded up $1.42 during trading on Friday, hitting $104.22. The stock had a trading volume of 921,567 shares, compared to its average volume of 987,658. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.83 and a current ratio of 0.88. The stock has a market capitalization of $13.85 billion, a price-to-earnings ratio of 16.52, a P/E/G ratio of 2.16 and a beta of 0.85. Quest Diagnostics has a one year low of $78.95 and a one year high of $107.97. The stock has a 50 day simple moving average of $103.00 and a 200 day simple moving average of $101.34.

In other news, CAO Michael J. Deppe sold 5,000 shares of Quest Diagnostics stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $106.00, for a total transaction of $530,000.00. Following the completion of the sale, the chief accounting officer now directly owns 28,671 shares in the company, valued at $3,039,126. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.86% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of DGX. Signaturefd LLC grew its holdings in Quest Diagnostics by 15.9% during the third quarter. Signaturefd LLC now owns 714 shares of the medical research company’s stock valued at $76,000 after purchasing an additional 98 shares during the last quarter. Acropolis Investment Management LLC boosted its position in shares of Quest Diagnostics by 2.2% in the third quarter. Acropolis Investment Management LLC now owns 4,700 shares of the medical research company’s stock valued at $503,000 after acquiring an additional 100 shares during the period. Berman Capital Advisors LLC boosted its position in shares of Quest Diagnostics by 47.7% in the second quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 103 shares during the period. Commerzbank Aktiengesellschaft FI boosted its position in shares of Quest Diagnostics by 2.9% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 3,661 shares of the medical research company’s stock valued at $392,000 after acquiring an additional 103 shares during the period. Finally, Financial Advantage Inc. boosted its position in shares of Quest Diagnostics by 0.3% in the second quarter. Financial Advantage Inc. now owns 30,316 shares of the medical research company’s stock valued at $3,086,000 after acquiring an additional 104 shares during the period. Institutional investors own 89.63% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading: What is the G-20?

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.